Testing a bladder cancer drug for high-risk NMIBC patients
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a drug called Disitamab Vedotin, given directly into the bladder, for a type of early bladder cancer (high-risk NMIBC) that has a protein called HER2. It aims to see if this treatment can help avoid more radical surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with high-risk non-muscle invasive bladder cancer (a fast-growing tumor that may have come back).
- After a procedure to remove visible tumors (TURBT), some disease may remain (flat spots called CIS are okay).
- Your tumor sample showed at least a 1+ level of a protein called HER2 (tested in the lab).
- You are between 18 and 75 years old.
- You are in good enough health to receive treatment (good heart, blood, liver, kidney function, and daily activity level 0-1).
- You are not fit for or choose not to have radical bladder removal surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, disitamab vedotin and ivonescimab, for people with muscle-invasive bladder cancer who cannot receive standard chemotherapy with cisplatin. The goal is to see if this treatment is safe and effective before surgery.
This trial is testing a combination of two drugs (disitamab vedotin and toripalimab) for people with muscle-invasive bladder cancer that has not spread. The goal is to see if this treatment can shrink the tumor before surgery. You may qualify if your tumor has a certain level of a protein called HER2.
This trial tests two drugs (RC48 and toripalimab) given before bladder cancer surgery for patients who cannot take the standard chemotherapy due to kidney problems or other reasons. The goal is to see if this combination can shrink the tumor and improve outcomes.
This study tests a new combination of an antibody-drug conjugate (a targeted therapy) with an immunotherapy drug, plus allergy and vitamin B12 medications, for advanced bladder cancer. It aims to see if this combo is safe and effective for people whose tumors have a certain marker called HER2.
This trial tests a combination of two medications—disitamab vedotin (a targeted therapy) and mitomycin C (a chemotherapy)—for people with early-stage bladder cancer that has a specific protein called HER2. The goal is to prevent cancer from coming back after surgery in people who cannot or will not receive BCG treatment.
This trial tests a combination of two drugs (disitamab vedotin and tislelizumab) given before a second bladder surgery (re-TURBT) for people with high-risk non-muscle invasive bladder cancer that has high HER2 levels. The goal is to see if this approach improves outcomes compared to standard care.
Hear when a new High Risk Non-muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.